Precigen, Inc. (PGEN)
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
- Symbol
- PGEN
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $2.82B
- 52 week range
- 2.99 - 8.04
Valuation
- Share price
- $7.44 (close of 2026-09-23)
- P/E (TTM)
- -7.44x
- Price to book
- 64.82x
- Price to free cash flow
- -24.52x
- Enterprise value
- $2.88B
- Book value per share
- $0.12
Price performance
| Period | Change |
|---|
| 1 day | -3.38% |
| 5 days | +6.29% |
| 1 month | +3.33% |
| 3 months | +38.81% |
| 6 months | +129.63% |
| Year to date | +77.99% |
| 1 year | +100.54% |
| 3 years | +431.43% |
| 5 years | +32.86% |
| 10 years | -72.62% |
| All time | -68.51% |
Profitability and growth
- Return on equity
- -1198.61%
- Return on invested capital
- -586.80%
- Return on assets
- -161.18%
- Return on capital employed
- -93.49%
- Gross margin
- 9.85%
- Net margin
- -2588.21%
- EBITDA margin
- -1108.10%
- Revenue growth
- 146.73%
- Net income growth
- -98.55%
- Free cash flow growth
- -17.03%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -4.08%
- Current ratio
- 4.58x
- Net debt to EBITDA
- -0.41x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $9.68M
- Cost of revenue
- $8.73M
- Gross profit
- $954.00K
- EBITDA
- $-107.31M
- Net income
- $-250.64M
- Earnings per share
- $-1.37
- Research and development
- $41.33M
- Shares outstanding
- 312.98M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $9.68M | $954.00K | $-250.64M | $-1.37 |
| 2024-12-31 | $3.92M | - | $-126.23M | $-0.47 |
| 2023-12-31 | $6.22M | - | $-95.90M | $-0.39 |
| 2022-12-31 | $26.91M | - | $28.32M | $0.14 |
| 2021-12-31 | $14.27M | - | $-92.17M | $-0.47 |
| 2020-12-31 | $31.99M | - | $-170.52M | $-1.02 |
| 2019-12-31 | $90.72M | - | $-322.32M | $-2.09 |
| 2018-12-31 | $151.18M | $36.78M | $-509.34M | $-3.93 |
| 2017-12-31 | $219.46M | $186.20M | $-117.02M | $-0.98 |
| 2016-12-31 | $190.93M | $153.22M | $-186.61M | $-1.58 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 9.85% | -2588.21% | -1198.61% | -586.80% |
| 2024-12-31 | - | -3216.18% | -327.77% | - |
| 2023-12-31 | - | -1540.63% | -80.93% | -158.39% |
| 2022-12-31 | - | 105.23% | 22.43% | - |
| 2021-12-31 | - | -646.01% | -85.86% | - |
| 2020-12-31 | - | -533.01% | -253.85% | - |
| 2019-12-31 | - | -355.29% | -449.48% | - |
| 2018-12-31 | 24.33% | -336.91% | -134.49% | -133.22% |
| 2017-12-31 | 84.84% | -53.32% | -21.41% | -28.72% |
| 2016-12-31 | 80.25% | -97.74% | -32.78% | -35.67% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $100.37M | $93.17M |
| 2024-12-31 | $97.91M | - |
| 2023-12-31 | $62.90M | - |
| 2022-12-31 | $55.95M | - |
| 2021-12-31 | $108.66M | $179.88M |
| 2020-12-31 | $100.12M | $171.52M |
| 2019-12-31 | $75.05M | $186.32M |
| 2018-12-31 | $222.46M | $211.22M |
| 2017-12-31 | $74.38M | $7.54M |
| 2016-12-31 | $237.21M | $7.56M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-89.83M | $10.87M |
| 2024-12-31 | $-76.76M | $9.47M |
| 2023-12-31 | $-68.47M | $9.89M |
| 2022-12-31 | $-69.97M | $10.21M |
| 2021-12-31 | $-63.02M | $13.90M |
| 2020-12-31 | $-84.55M | $18.37M |
| 2019-12-31 | $-173.81M | $18.95M |
| 2018-12-31 | $-165.83M | $36.30M |
| 2017-12-31 | $-150.39M | $41.58M |
| 2016-12-31 | $-80.62M | $42.20M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-12
- Consensus EPS estimate
- $0.09
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-04 | Jun/2026 | - |
| 2026-05-13 | - | - |
| 2026-03-25 | - | - |
| 2025-11-13 | - | - |
| 2025-08-12 | - | - |
| 2025-05-14 | - | - |
| 2025-03-19 | - | - |
| 2024-11-14 | - | - |
Filings and sources
- Company website
- precigen.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades